Table 6. Performance of the Revised Bethesda Guidelines (2004) and accuracy of the Amsterdam II criteria against the molecular tumour analyses.
|
Molecular tumour analyses
|
|||
|---|---|---|---|
| Lynch syndrome likely | Lynch syndrome not likely | ||
| Revised Bethesda Guidelines (RBG) | |||
| Positive | 6 | 81 | 87 |
| Negative | 6 | 243 | 249 |
| 12 | 324 | 336 | |
| Amsterdam II criteria (AM II) | |||
| Positive | 3 | 5 | 8 |
| Negative | 9 | 319 | 328 |
| 12 | 324 | 336 | |
Abbreviations: CI=confidence interval; PPV=positive predictive value.
RBG: Sensitivity 50% (95% CI, 21–79%); specificity 75% (95% CI, 70–80%), PPV 7% (95% CI, 3–14%).
AM II: Sensitivity 25% (95% CI, 6–57%), specificity 98% (95% CI, 96–99%), PPV 38% (95% CI, 9–76%).